A coroner found there were "missed opportunities" to treat a 38-year-old woman with cancer. Carla Smith, 38, who died on 7 ...

The US Food and Drug Administration (FDA) has granted breakthrough device designation for Acrivon Therapeutics’ ACR-368 ...

Endometrial cancer (EC) ranks as the second most prevalent gynecologic malignancy globally, with approximately 189,000 new ...

The ACR-368-tailored OncoSignature assay is being used to predict patients most likely to respond to ACR-368 in Acrivon’s ongoing, ...

Acrivon Therapeutics said the Food and Drug Administration has granted Breakthrough Device designation for its ACR-368 OncoSignature assay, an immunofluorescence assay for the identification of ...

The addition of radiation to chemotherapy did not improve overall survival in patients with locally advanced endometrial cancer, a recent phase 3 trial found.

The in-house salon for patients at Roswell Park will now be called the New Era Cap Foundation Elevate Salon. BUFFALO, N.Y. — ...

Lenvima plus Keytruda did not significantly improve survival or progression-free survival compared to chemotherapy in advanced endometrial cancer. The study involved 842 patients, with no new safety ...

Cancer rates are declining, but young women are being diagnosed more frequently. Learn about the current trends and research ...

Dee Morris is planning her next vacation -and that’s a big deal when considering that not long ago, her world was turned ...

The European Commission (EC) has approved GSK's Jemperli (dostarlimab) combined with chemotherapy that includes carboplatin and paclitaxel for the first-line treatment of primary advanced or recurrent ...

“While endometrial cancer is easily treated with early detection, late detection frequently requires invasive treatments like hysterectomy. In a younger woman who would like to have ...